Longevity · 8 min read · Published September 8, 2026

NMN vs NR vs NAD+: The 2026 Head-to-Head Human Trials, and Who Funded the Comparisons

Two human trials in 2026 finally compared NMN and NR directly and reached different conclusions. What each measured, what neither showed, why Amazon pulled NMN, and how to read a comparison written by a company that sells one of them.

Is NMN or NR better for raising NAD+?

Two 2026 human head-to-head trials disagree. A 65-person Nature Metabolism study found 1,000 mg of NR or NMN each roughly doubled blood NAD+ in 14 days with no significant difference. A 12-person iScience study found NR raised blood NAD+ about 2.3 times more than NMN. Neither has shown an anti-aging outcome in humans.

NAD+ (nicotinamide adenine dinucleotide) is the coenzyme that cellular energy production and the sirtuin and PARP enzyme families all depend on. Levels fall with age in several tissues, and restoring them extended healthspan in mice, which launched a supplement category worth billions. Two molecules dominate it: nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Until 2026 nobody had compared them properly in people.

The two 2026 trials

How can both be right? Different doses, different durations, different assays (whole blood versus specific metabolite panels) and, above all, different sample sizes. A 12-person crossover can detect a large difference and miss a small one; a 65-person parallel-group trial can miss a modest difference between two active arms. The safe reading is that both precursors raise blood NAD+ substantially and that any difference between them is smaller than the difference between taking one and taking nothing.

The original human NR data came from a 2016 Nature Communications trial (PMC8444956 review); the best NMN data include a 2023 randomized trial in middle-aged adults (PMC10459282) showing raised NAD+ and a modest walking-distance improvement.

What neither trial shows

• That higher blood NAD+ translates to higher NAD+ inside muscle, liver or brain at meaningful levels (the iScience brain result is the first signal, and it took four weeks).
• That any clinical outcome improves: no trial of NR or NMN has shown slower aging, better cognition or lower disease risk in healthy people.
• That long-term use is safe. The largest trials ran weeks to months. A raised methylation demand (precursors are eventually methylated to be excreted) is the reason some researchers pair them with methyl donors, an idea with no outcome data.

Who writes the comparisons you find on Google

Search 'NMN vs NR' and the top results include aboutnad.com and truniagen.com, both properties of Niagen Bioscience (formerly ChromaDex), which sells NR and holds its patents. On the other side, nmn.com and several 'longevity' blogs are NMN retailers. That does not make their science wrong; the Nestle trial above is, after all, industry-funded and published in a top journal. It means you should expect each to emphasize the trial that favors its product, and you should look for the trial IDs and read the primary papers.

Why did Amazon stop selling NMN?

In late 2022 the FDA stated that NMN could not be marketed as a dietary supplement because it had been authorized for investigation as a new drug before being sold as a supplement, the same 'drug exclusion' rule that hit NAC. Amazon delisted NMN products in early 2023. The Natural Products Association petitioned the FDA, the FDA's position was challenged, and NMN returned to many retailers; the legal status remains contested rather than settled.

For NR, the FDA accepted new-dietary-ingredient and GRAS notifications years earlier, which is why NR never faced the same problem. This regulatory difference, not efficacy, is the main practical difference between the two in the United States.

Is it safe to take NR and NMN together?

No trial has tested the combination, and there is no biological reason to expect an additive effect: NMN is converted to NR outside cells before uptake in many tissues, so the two feed the same pathway. Taking both mainly doubles the dose. Reported side effects of each alone are mild (flushing, nausea, digestive upset) in the trials to date.

Where the other precursors fit

• NAD+ itself, given intravenously or as a nasal spray, has no controlled trial showing it enters cells intact; it is broken down to nicotinamide and NR in blood.
• Plain nicotinamide (vitamin B3) is cheap and raises NAD+ in some contexts, but in the Nestle trial it did not raise whole-blood NAD+ and did raise homocysteine.
• Trigonelline, a coffee alkaloid identified as an NAD+ precursor in 2024, improved muscle function in old mice and has no human intervention trial.
• 5-amino-1MQ is often sold alongside these because it inhibits NNMT, the enzyme that consumes nicotinamide; it is a small molecule with mouse data only.

The bottom line

Both NR and NMN reliably raise blood NAD+ in humans. Whether one does it better depends on which 2026 trial you weight more, and the honest answer is that the difference, if real, is modest. What no trial has shown is that this changes how anyone ages. That is the claim that sells the product, and it is the one still waiting for evidence.